213 related articles for article (PubMed ID: 22671928)
21. Bone marrow microenvironment and the identification of new targets for myeloma therapy.
Podar K; Chauhan D; Anderson KC
Leukemia; 2009 Jan; 23(1):10-24. PubMed ID: 18843284
[TBL] [Abstract][Full Text] [Related]
22. Recent advances in the treatment of Multiple Myeloma.
Yasui H; Hideshima T; Richardson PG; Anderson KC
Curr Pharm Biotechnol; 2006 Oct; 7(5):381-93. PubMed ID: 17076653
[TBL] [Abstract][Full Text] [Related]
23. Lenalidomide and its role in the management of multiple myeloma.
Falco P; Cavallo F; Larocca A; Liberati AM; Musto P; Boccadoro M; Palumbo A
Expert Rev Anticancer Ther; 2008 Jun; 8(6):865-74. PubMed ID: 18533796
[TBL] [Abstract][Full Text] [Related]
24. Molecular targets for the treatment of multiple myeloma.
Rossi M; Di Martino MT; Morelli E; Leotta M; Rizzo A; Grimaldi A; Misso G; Tassone P; Caraglia M
Curr Cancer Drug Targets; 2012 Sep; 12(7):757-67. PubMed ID: 22671925
[TBL] [Abstract][Full Text] [Related]
25. Novel therapies in the treatment of multiple myeloma.
Laubach JP; Mitsiades CS; Mahindra A; Schlossman RL; Hideshima T; Chauhan D; Carreau NA; Ghobrial IM; Raje N; Munshi NC; Anderson KC; Richardson PG
J Natl Compr Canc Netw; 2009 Oct; 7(9):947-60. PubMed ID: 19878638
[TBL] [Abstract][Full Text] [Related]
26. The emerging role of novel therapies for the treatment of relapsed myeloma.
Richardson PG; Hideshima T; Mitsiades C; Anderson KC
J Natl Compr Canc Netw; 2007 Feb; 5(2):149-62. PubMed ID: 17335684
[TBL] [Abstract][Full Text] [Related]
27. [Daratumumab--breakthrough drug in multiple myeloma therapy].
Jurczyszyn A; Kosmaczewska A; Skotnicki AB
Postepy Hig Med Dosw (Online); 2014 Nov; 68():1352-60. PubMed ID: 25531698
[TBL] [Abstract][Full Text] [Related]
28. Tipifarnib and bortezomib are synergistic and overcome cell adhesion-mediated drug resistance in multiple myeloma and acute myeloid leukemia.
Yanamandra N; Colaco NM; Parquet NA; Buzzeo RW; Boulware D; Wright G; Perez LE; Dalton WS; Beaupre DM
Clin Cancer Res; 2006 Jan; 12(2):591-9. PubMed ID: 16428505
[TBL] [Abstract][Full Text] [Related]
29. Deacetylase inhibitors: an advance in myeloma therapy?
Laubach JP; San-Miguel JF; Hungria V; Hou J; Moreau P; Lonial S; Lee JH; Einsele H; Alsina M; Richardson PG
Expert Rev Hematol; 2017 Mar; 10(3):229-237. PubMed ID: 28076695
[TBL] [Abstract][Full Text] [Related]
30. [Molecular targeting therapy for multiple myeloma].
Takatoku M
Nihon Rinsho; 2007 Dec; 65(12):2345-50. PubMed ID: 18069281
[TBL] [Abstract][Full Text] [Related]
31. (Bortezomib plus lenalidomide/thalidomide)- vs. (bortezomib or lenalidomide/thalidomide)-containing regimens as induction therapy in newly diagnosed multiple myeloma: a meta-analysis of randomized controlled trials.
Wang A; Duan Q; Liu X; Ding K; Han Y; Zhu W; Cai X; Wu J; Sun Z
Ann Hematol; 2012 Nov; 91(11):1779-84. PubMed ID: 22773209
[TBL] [Abstract][Full Text] [Related]
32. Multiple myeloma.
Raab MS; Podar K; Breitkreutz I; Richardson PG; Anderson KC
Lancet; 2009 Jul; 374(9686):324-39. PubMed ID: 19541364
[TBL] [Abstract][Full Text] [Related]
33. Targeted therapy of multiple myeloma based upon tumor-microenvironmental interactions.
Anderson KC
Exp Hematol; 2007 Apr; 35(4 Suppl 1):155-62. PubMed ID: 17379101
[TBL] [Abstract][Full Text] [Related]
34. Diagnosis and the current trends in multiple myeloma therapy.
Dmoszyńska A
Pol Arch Med Wewn; 2008 Oct; 118(10):563-6. PubMed ID: 19112817
[TBL] [Abstract][Full Text] [Related]
35. Oncogenomics to target myeloma in the bone marrow microenvironment.
Anderson KC
Clin Cancer Res; 2011 Mar; 17(6):1225-33. PubMed ID: 21411438
[TBL] [Abstract][Full Text] [Related]
36. Understanding novel therapeutic agents for multiple myeloma.
Tariman JD
Clin J Oncol Nurs; 2003; 7(5):521-8. PubMed ID: 14603548
[TBL] [Abstract][Full Text] [Related]
37. CD38 Monoclonal Antibody Therapies for Multiple Myeloma.
Wong SW; Comenzo RL
Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):635-45. PubMed ID: 26443328
[TBL] [Abstract][Full Text] [Related]
38. Targeted therapy in multiple myeloma.
Chng WJ; Lau LG; Yusof N; Mow BM
Cancer Control; 2005 Apr; 12(2):91-104. PubMed ID: 15855892
[TBL] [Abstract][Full Text] [Related]
39. New drugs for myeloma.
Richardson PG; Mitsiades C; Schlossman R; Munshi N; Anderson K
Oncologist; 2007 Jun; 12(6):664-89. PubMed ID: 17602058
[TBL] [Abstract][Full Text] [Related]
40. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets.
Hideshima T; Mitsiades C; Tonon G; Richardson PG; Anderson KC
Nat Rev Cancer; 2007 Aug; 7(8):585-98. PubMed ID: 17646864
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
